Press Releases May 8, 2026 08:30 AM

Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference

Aclaris Therapeutics to present at the 2026 Bank of America Healthcare Conference

By Maya Rios
Share
Twitter Reddit Facebook LinkedIn
ACRS

Aclaris Therapeutics, a clinical-stage biopharmaceutical company, announced it will participate in the 2026 Bank of America Healthcare Conference where its President and COO will present the company's pipeline and developments. The presentation will be webcast live and archived for investor access.

Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference
ACRS
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Aclaris Therapeutics is focused on developing novel treatments for immuno-inflammatory diseases.
  • The company will present at a major healthcare conference, providing an update on its clinical-stage product candidates.
  • Aclaris maintains a robust R&D engine with a multi-stage portfolio addressing unmet medical needs in the immuno-inflammatory sector.

WAYNE, Pa., May 08, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Thursday May 14, 2026, at 9:35 AM PT, Aclaris’ President and Chief Operating Officer Dr. Hugh Davis will provide a corporate presentation during the 2026 Bank of America Healthcare Conference in Las Vegas, NV.

A live and archived webcast of this event will be accessible on the Events page of the Aclaris website, www.aclaristx.com. The webcast will be available on the Aclaris website for at least 30 days.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on LinkedIn.

Aclaris Therapeutics Contact:

Will Roberts
Senior Vice President
Corporate Communications and Investor Relations
(484) 329-2125
[email protected]


Risks

  • Clinical-stage biopharmaceutical companies face regulatory and development risks which could impact future product approvals and marketability.
  • The company’s treatments are for immuno-inflammatory diseases with currently unsatisfactory treatment options, indicating potential market and reimbursement uncertainties.
  • No new data or breakthroughs were announced in this release; investor reaction may depend on content revealed during the presentation, which carries typical execution and communication risks.

More from Press Releases

Nocera Expands Diversified Technology Strategy With Binding Agreement to Acquire an Equity Interest in INERGX, an Integrated Energy Storage and Power Platform for AI, Defense and Mission-Critical Demand Jul 8, 2026 60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases Jul 8, 2026 EXL Schedules Second Quarter 2026 Financial Results Conference Call Jul 8, 2026 Magnite to Announce Second Quarter 2026 Financial Results on August 5, 2026 Jul 8, 2026 Aptorum Group and DiamiR Biosciences Announce Three Presentations at 2026 Alzheimer’s Association International Conference Jul 8, 2026